Adult and Adolescent Vaccines Market to 2017 - AcceleratedDevelopment and Introduction Plans (ADIP) by GAVI Allianceto Drive Growth
By 2017, the Global Vaccines Market is Expected to Generate More than Twice the Annual Revenue of 2010 The global vaccines industry was valued at $28 billion in 2010, and is expected to reach $56.7 billion in 2017, at a Compounded Annual Growth Rate (CAGR) of 11.5%. The vaccines market, which was once considered a low-profit segment of the top players’ portfolios, showed a turnaround after the resounding success of Prevnar, the first blockbuster vaccine. The ability of vaccines to generate high revenues and profits despite being priced at a premium has proven attractive to both existing players in the market and to big pharmaceutical companies who have been watching the development of the market with interest. The increase in revenues and growth rates came at a time when the pharmaceutical industry was under huge pressure from patent expiries and weakened pipelines. The pharmaceutical industry has been intent on strengthening their revenue streams and streamlining operations through layoffs and shutdowns of manufacturing and R&D operations. The success of premium priced vaccines such as Prevnar13 has prompted big pharmaceutical players such as Pfizer and AstraZeneca to invest in the vaccines industry, which promises safe revenues due to a lack of threat from generics. Limitation in Production Capacity Delays Realization of Potential
The global vaccines industry has always faced the problem of maintaining the optimal production capacity to meet the requirements of the target population. There have been several cases of shortages of important vaccines in the industry, which have led to an increase in the incidence of diseases. The shortage of Prevnar in 2001 caused a panic in the US due to increasing concerns about the rise in incidence of meningitis and pneumonia. Wyeth (now Pfizer) had only 60% of production capacity available for distribution. Such shortages not only decrease sales of the vaccines but also increase the incidence of diseases. In the case of influenza pandemics, the production of seasonal flu vaccines has to be stopped abruptly to manufacture pandemic vaccines. However, the production volume from seasonal flu manufacturing facilities does not suffice for the entire population. The shortage of doses is also accentuated by the lengthy timeframe required for manufacturing these vaccines using eggs. While several vaccine technologies such as cell-based manufacturing, DNA vaccines, and novel adjuvants have been introduced to solve this problem, there is still a need to increase production capacities to meet demands. Licensing and Co-Development Agreements Accounted for 73% of the Strategic Consolidations GBI Research’s analysis shows that licensing and co-development agreements are characteristic of the global vaccines market, where technologies and development
For further details, please click or add the below link to your browser: http://gbiresearch.com/Report.aspx?ID=Adult-and-Adolescent-Vaccines-Market-to-2017-Accelerated-Development-and-Introduction-Plans-%28ADIP%29-by-GAVI-Alliance-to-Drive-Growth&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare&CompanyID=ssrve platforms are highly dispersed among small and big companies. Smaller vaccine companies that do not have the financial muscle to compete against the top vaccine players make use of their technologies to generate revenues through royalties and through other revenue sharing agreements. Also, a number of public-private partnerships help the vaccines industry to develop interventions for new diseases. The global vaccines industry is a difficult industry for smaller companies to succeed in due to the high development costs required for licensing, acquisitions, marketing and manufacturing. Vaccine companies with promising candidates in the pipeline engage in out-licensing agreements with the top players, who in turn provide marketing, sales, and regulatory support. However, the vaccines industry remains an attractive one for large and small companies alike due to its potential to generate revenues from smaller disease populations too. Hence, the vaccines industry is expected to remain highly active in the future, fueled by the encouragement and financing from governments and other health organizations.
GBI Research, the leading business intelligence provider, has released its latest research, “Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth”, which provides insights into the global vaccines market forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline. GBI Research’s analysis shows that the overall global vaccines market was valued at $28 billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for the forecast period, and will reach $56.7 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage, and those in the later stages of development. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. For further details, please click or add the below link to your browser: http://gbiresearch.com/Report.aspx?ID=Adult-and-Adolescent-Vaccines-Market-to-2017-Accelerated-Development-and-Introduction-Plans-%28ADIP%29-by-GAVI-Alliance-to-Drive-Growth&ReportType=Industry_Report&coreindustry=ALL&Title=Pharmaceuticals_and_Healthcare&CompanyID=ssrve
Visit our report store: http://www.gbiresearch.com For more details contact: firstname.lastname@example.org North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782